Cell biologist Shawn Hingtgen, Ph.D., is convinced that stem cells can effectively treat brain cancer. Using the support he received through the mentored career development program offered by NCATS' Clinical and Translational Science Awards (CTSA) Program, he has collaborated with neurosurgeons, oncologists, stem cell experts, drug development specialists and others to create a potential therapy for glioblastoma multiforme, a deadly type of brain cancer.
Hingtgen, an assistant professor in the Eshelman School of Pharmacy at the University of North Carolina (UNC) at Chapel Hill, previously was an NCATS KL2 Mentored Clinical Research Scholar at the North Carolina Translational and Clinical Sciences (NC TraCS) Institute. Among other things, this award supports mentored career development for investigators who have recently completed professional training and are early in their research careers.
"The multidisciplinary nature of [the] NC TraCS KL2 program enables junior faculty to work with experts in many different fields to solve problems and provide guidance in the process of translating basic science knowledge to clinical medicine," said Kim Boggess, M.D., UNC professor of obstetrics and gynecology and co-director of the NC TraCS KL2 program.
The UNC Health Care System (UNCHCS) is part of an effort to determine the best ways to perform surgery for obesity. Working with a national collaboration, we are examining weight loss outcomes of bariatric surgery as part of a consortium that can efficiently and securely examine tens of thousands of patient records. Sponsored by the Patient Centered Outcome Research Institute (PCORI), the effort will provide needed information to patients and their physicians regarding the best type of surgery for a given individual.
Jessica Craddock, a patient who knows firsthand what it is like to have this kind of surgery, shares that "Bariatric surgery has the promise of not only changing people's lives but saving them as well. In under a year and a half I have lost nearly 300 lbs., and am cured of uncontrollable diabetes and hypertension. My arthritis and psoriasis are all but gone and my quality of life is what it should be for a 26 year old female."
Anna Kahkoska and Nick Brazeau, students in UNC’s MD-PhD program, have developed an innovative approach to patient care at the Open Door Clinic, a free clinic in Burlington staffed by students from the UNC School of Medicine, Elon University, and Alamance Community College that treats a large number of patients with diabetes.
In North Carolina, 1 in 10 people have diabetes. That includes a large number of patients at the Open Door Clinic, a free, student-run clinic in Burlington staffed by volunteers from Elon University, Alamance Community College, and the UNC School of Medicine. Two years ago, Anna Kahkoska and Nick Brazeau took a direct leadership role in the Diabetes Maintenance and Prevention Program, where they were responsible for coordinating a monthly Endocrinology clinic for patients with diabetes referred from the general clinic for specialized care.
What started as a way to do some good in the community while also gaining valuable clinical skills quickly morphed into something much larger. When they began working at Open Door, Brazeau said the continuity of care was lacking. Patients would come to clinic one month, and then miss several subsequent visits due to changes in work hours, childcare responsibilities or other issues. When they did come back, they were frustrated with long waits.
UNC and Duke researchers receive CTSA Consortium Collaborative Pilot Award to develop a new way to study cancer
For doctors and patients, the fight against cancer can be a lot like an exceedingly tricky version of the classic arcade game of whack-a-mole. You might beat back a tumor or part of a tumor, only to have another one pop up. To make matters worse, the "mallet" or treatment that successfully whacks the first tumor cells doesn't always work on those arising later. You might need a new strategy or even an entirely different drug. It's a tough game to win.
The reason it is often unsuccessful to apply a singular approach to beating cancer is that cancer cells evolve and change over time as cells divide and tumors expand. That ever-changing, increasingly heterogeneous nature of cancer has been a particular problem in effectively treating glioblastoma multiforme, a common and aggressive form of brain cancer. Even when treated with cancer-fighting drugs, only one out of three patients with glioblastoma multiforme are alive two years after their diagnosis.
"There might be a drug that works against the founding mutation in a tumor, but now this branch diverged and might then show resistance," explained Albert Baldwin, Professor and Associate Director of Basic Research at University of North Carolina at Chapel Hill's Lineberger Comprehensive Cancer Center.